Inovio Pharmaceuticals Shares Outstanding 2006-2021 | INO

Inovio Pharmaceuticals shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Inovio Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 155
2019 99
2018 93
2017 82
2016 73
2015 68
2014 59
2013 46
2012 34
2011 32
2010 26
2009 19
2008 11
2007 10
2006 8
2005 5
Inovio Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 210
2021-03-31 202
2020-12-31 155
2020-09-30 174
2020-06-30 156
2020-03-31 125
2019-12-31 99
2019-09-30 103
2019-06-30 98
2019-03-31 97
2018-12-31 93
2018-09-30 92
2018-06-30 91
2018-03-31 90
2017-12-31 82
2017-09-30 87
2017-06-30 75
2017-03-31 74
2016-12-31 73
2016-09-30 74
2016-06-30 73
2016-03-31 72
2015-12-31 68
2015-09-30 74
2015-06-30 68
2015-03-31 61
2014-12-31 59
2014-09-30 61
2014-06-30 60
2014-03-31 55
2013-12-31 46
2013-09-30 48
2013-06-30 45
2013-03-31 39
2012-12-31 34
2012-09-30 34
2012-06-30 34
2012-03-31 34
2011-12-31 32
2011-09-30 32
2011-06-30 32
2011-03-31 30
2010-12-31 26
2010-09-30 26
2010-06-30 26
2010-03-31 26
2009-12-31 19
2009-09-30 23
2009-06-30 14
2009-03-31 11
2008-12-31 11
2008-09-30 11
2008-06-30 11
2008-03-31 11
2007-12-31 10
2007-09-30 11
2007-06-30 10
2007-03-31 9
2006-12-31 8
2006-09-30 8
2006-06-30 8
2006-03-31 7
2005-12-31 5
2005-09-30 5
2005-06-30 5
2005-03-31 5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.481B $0.007B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57